REG - BioPharma Credit PLC - UPDATES ON INVESTMENT PORTFOLIO

Biopharma CreditAnnouncement

21/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251021:nRSU1134Ea&default-theme=true

RNS Number : 1134E  BioPharma Credit PLC  21 October 2025

21 October 2025

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

UPDATES ON INVESTMENT PORTFOLIO

 

BioCryst Pharmaceuticals, Inc. - European ORLADEYO® Sale Completion and Final
Loan Repayment

 

Pharmakon Advisors, LP, the investment manager of the Company, provides the
following update subsequent to the announcement released on 1 October 2025 by
BioCryst Pharmaceuticals, Inc. ("BioCryst") regarding the completion of the
sale of its European ORLADEYO® (berotralsat) business to Neopharmed Gentili
(the "Transaction"). The Company had previously noted on 1 July 2025
BioCryst's initial announcement with respect to the Transaction, and
BioCryst's plans to use the proceeds from the Transaction to retire all
remaining term debt existing under the loan agreement with its lenders.

 

The Company had previously announced on 19 April 2023 an investment in a
senior secured loan to BioCryst for up to US$180 million in up to four
tranches.  The Company funded US$120 million at closing and BioCryst did not
draw on the remaining three tranches. At the time of the final repayment on 7
October 2025, US$199 million of outstanding term debt remained from the
original US$300 million term loan funded at closing, of which US$79.5 million
remained from the Company's original investment of US$120 million. In
connection with this final repayment, the Company received US$2.6 million of
accrued interest and prepayment fees.

 

Valneva Austria GmbH - Closing of Tranche A Funding

 

On 17 October 2025, the Company funded its investment of US$30 million to
Valneva Austria GmbH, a subsidiary of Valneva SE ("Valneva"), with BioPharma
Credit Investments V (Master) LP ("BioPharma-V") also concurrently investing
US$185 million as part of the Tranche A funding. The Company had previously
announced on 7 October 2025 the entering into a senior secured loan agreement
with Valneva and BioPharma-V, which included an initial tranche of US$215
million as well as further tranches of US$285 million for potential business
development (subject to mutual agreement by the parties with loan allocations
to be determined at such time).

 

 

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCURVKRVBURUAA



            Copyright 2019 Regulatory News Service, all rights reserved